Drug Information

Drug General Information
Drug ID
D0P2SI
Former ID
DNCL002477
Drug Name
Galiximab
Drug Type
Antibody
Indication Lymphoma [ICD9: 202.8, 208.9; ICD10:C81-C86] Phase 2 [522087]
Company
Biogen Idec
CAS Number
CAS 357613-77-5
Target and Pathway
Target(s) T-lymphocyte activation antigen CD80 Target Info [527618]
KEGG Pathway Cell adhesion molecules (CAMs)
Toll-like receptor signaling pathway
Intestinal immune network for IgA production
Type I diabetes mellitus
Autoimmune thyroid disease
Systemic lupus erythematosus
Rheumatoid arthritis
Allograft rejection
Graft-versus-host disease
Viral myocarditis
NetPath Pathway Leptin Signaling Pathway
RANKL Signaling Pathway
PANTHER Pathway T cell activation
Pathway Interaction Database TCR signaling in na&#xef
TCR signaling in na&#xef
IL12 signaling mediated by STAT4
Reactome PIP3 activates AKT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
CD28 dependent Vav1 pathway
CTLA4 inhibitory signaling
WikiPathways Toll-like receptor signaling pathway
Inflammatory Response Pathway
PIP3 activates AKT signaling
Primary Focal Segmental Glomerulosclerosis FSGS
Allograft Rejection
Costimulation by the CD28 family
Regulation of toll-like receptor signaling pathway
References
Ref 522087ClinicalTrials.gov (NCT00516217) Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma. U.S. National Institutes of Health.
Ref 527618Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol. 2005 Jul 1;23(19):4390-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.